期刊文献+

神经母细胞瘤临床分析 被引量:2

下载PDF
导出
摘要 目的探讨神经母细胞瘤(NB)患者的临床特征,复发难治NB患者治疗及疾病预后因素。方法对36例NB患者的临床特征进行统计描述;对其中13例复发难治性NB者采用EP方案及开普拓方案两种治疗方案进行对比及预后相关因素分析。结果 NB患者多以腹痛,腹部肿物及骨痛就诊。就诊时多有肝脏肿大,骨损伤。患者肿瘤原发部位常见于腹部及胸部。腹部肿物又以腹膜后及肾上腺居多。结论复发难治性NB患者采用EP方案和开普拓方案二者生存率及有效率无明显差异;疾病的预后与肿瘤的大小及部位无关,而与年龄、疾病分期及手术切除完整性有关,血清铁蛋白及血清神经元特异性烯醇化酶可作为肿瘤负荷的指标。
作者 刘娜
出处 《齐齐哈尔医学院学报》 2013年第12期1732-1734,共3页 Journal of Qiqihar Medical University
  • 相关文献

参考文献4

  • 1Strenger V,Kerbl R, Dombusch HJ, et al. “ Diagnostic andprognostic impact of urinary catecholamines in neuroblastomapatients”. Pediatr Blood Cancer,2007,48(5) :504-509.
  • 2Pashankar F, 0 Dorisio M, Menda Y. “ MIBG and somatostatinreceptor analogs in children : current concepts on diagnostic andtherapeutic use' Journal of Nuclear Medicine, 2005, 46 ( 1Suppl)) ;55S-61S. PMID 15653652.
  • 3Miura K,Mineta H,Yokota N,Tsutsui Y. “Olfactory neuroblastomawith epithelial and endocrine differentiation transformed intoganglioneuroma after chemoradiotherapy,,. Pathol. Int, 2001, 51(12):942-7.
  • 4Response and toxicity to a dose-intensive multi-ent chemotherapyinduction regimen for high risk neuroblastoma ( HR-NB ) : AChildren's Oncology Group ( COG A3973 ) study. - ASCO".http://www. asco. org/ASCO/Abstracts +% 26 + Virtual +Meeting/Abstracts. &vmview = abst _ detail _ view&conflD =47&abstractID =31659. Retrieved 2008-02-02.

同被引文献27

  • 1高晓宁,唐锁勤,林季.晚期儿童神经母细胞瘤的临床和预后分析[J].中国当代儿科杂志,2007,9(4):351-354. 被引量:7
  • 2Marls JM. Recent advances in neuroblastoma. N Engl J Med, 2010, 362:2202-2211.
  • 3Park JR, Bagatell R, London WB, et al. Children' s Oncology gToup' S 2013 blueprint for research : neuroblastoma. Pediatr Blood Cancer, 2013, 60: 985-993.
  • 4Hisashige A. Effectiveness of National Screening Program for Neuroblastoma in Japan. Glob J Health Sci, 2014, 6:94-106.
  • 5Parodi F, Passonli L, Massimo L, et al. Identification of Novel Prognostic Markers in Relapsing Localized Referable Neuroblastoma. OMICS, 2011, 15:113-121.
  • 6Pinto NR. , Applebaum MA,, Volchenboum SL, et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol, 2015, 33: 3008-3017.
  • 7Takeda T, Hatae Y, Nakadate H, et al. Japanese experience of screening. Med Pediatr Oncol, 1989, 17: 368-372.
  • 8Katanoda K, Hayashi K, Yamamoto K, et al. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan. Epidemiol, 2009, 19: 266-270.
  • 9Arakawa A, Oquma E, Aihara T, et al. Long-term follow up of the observation for neuroblastoma detected at 6-month mass screening. pediar, 2014, 165: 855-857.
  • 10Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med, 2002, 346 : 1047-1053.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部